Results 181 to 190 of about 314,849 (336)

Comprehensive Framework for Oncology Pharmacist‐Led Parenteral Anticancer Therapy Patient Education: The Opinion of the American College of Clinical Pharmacy Hematology/Oncology Practice and Research Network

open access: yesJACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, EarlyView.
This narrative review summarizes evidence for effective patient education on parenteral anticancer therapies. The authors propose a structured framework for oncology pharmacist‐led patient education on parenteral anticancer therapies that combines pharmacotherapy knowledge and the application of patient‐centered care.
Erin Hickey Zacholski   +7 more
wiley   +1 more source

Splenectomy for thrombocytopenia in chronic granulocytic leukemia [PDF]

open access: bronze, 1972
George P. Canellos   +2 more
openalex   +1 more source

Severe Malnutrition Identified by the Controlling Nutritional Status (CONUT) Score Is Associated With Prolonged Intensive Care Unit (ICU) Stay in Pneumonia Complicated With Respiratory Failure Patients Who Underwent Invasive Mechanical Ventilation

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
This study was to evaluate the relationship between Controlled Nutritional Status(CONUT) score and prolonged ICU stay in patients with pneumonia complicated by respiratory failure who underwent invasive mechanical ventilation. CONUT severe grade, history of smoking, hypertension, and blood transfusion were independently associated with prolonged ICU ...
Zhijuan Zheng, Guixia Peng, Yue Xiao
wiley   +1 more source

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Idecabtagene vicleucel (ide‐cel, ABECMA) is an autologous, B‐cell maturation antigen‐directed, chimeric antigen receptor (CAR) T‐cell therapy, which has demonstrated significantly improved progression‐free survival (PFS) and overall response rate (ORR) in patients with triple‐class‐exposed relapsed/refractory multiple myeloma (TCE RRMM). Here,
Fan Wu   +11 more
wiley   +1 more source

Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Valemetostat is a dual inhibitor of EZH2/1 approved in Japan for the treatment of relapsed/refractory (R/R) adult T–cell lymphoma/leukemia (ATLL) and R/R peripheral T–cell lymphoma (PTCL). It is administered orally once daily (QD) at 200 mg. Here, we present comprehensive population pharmacokinetic (PPK) and exposure–response (ER) analyses of ...
Hiroyuki Inoue   +7 more
wiley   +1 more source

THROMBOCYTOPENIA WITH ABSENT RADIUS (TAR)

open access: bronze, 1969
Judith G. Hall   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy